CAS 1446090-79-4

Formula: C25H17F3N4O3

InChI: InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1

InChI key: NGFFVZQXSRKHBM-FKBYEOEOSA-N

SMILES: C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F

Lifirafenib

CAS: 1446090-79-4

Purity: 99%

Ref: IN-DA001JUO

Lifirafenib

CAS: 1446090-79-4

Lifirafenib

Formula: C₂₅H₁₇F₃N₄O₃

Purity: ≥95%

Molecular weight: 478.42

Ref: 54-BUP03697

Lifirafenib

CAS: 1446090-79-4

Formula: C₂₅H₁₇F₃N₄O₃

Molecular weight: 478.43

Ref: 4Z-L-240001

Lifirafenib

CAS: 1446090-79-4

5-(((1R,1aS,6bR)-1-(6-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one

Formula: C₂₅H₁₇F₃N₄O₃

Purity: 98%

Molecular weight: 478.42

Ref: IN-DG632486

Lifirafenib

CAS: 1446090-79-4

Lifirafenib is a potent and selective kinase inhibitor, which is synthetically derived. It operates by targeting and inhibiting specific pathways involving the RAF kinases within the MAPK/ERK signaling cascade. This interruption is critical in the control of cellular proliferation and survival, pathways often dysregulated in various cancers. Lifirafenib is particularly effective against BRAF-mutant cancers, including melanoma and certain types of thyroid and colorectal cancers.

Formula: C₂₅H₁₇F₃N₄O₃

Purity: Min. 95%

Molecular weight: 478.42 g/mol

Ref: 3D-WHC09079

Lifirafenib

CAS: 1446090-79-4

Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant

Formula: C₂₅H₁₇F₃N₄O₃

Purity: 97.99% - 98%

Color and Shape: Solid

Molecular weight: 478.42

Ref: TM-T22272